Aveo, former execs reach $15M settlement with shareholders over 2013 drug rejection

Investors had accused the Cambridge biotech and the former executives of concealing issues with a kidney cancer drug before it was rejected.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news